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Abstract
Background: The clinical predictors of aromatase inhibitor-related arthralgia (AIA), a drug-related adverse reaction
of aromatase inhibitors (AIs), remain unclear.
Methods: AIA was prospectively surveyed every 4 months in 328 postmenopausal breast cancer patients
administered a non-steroidal AI (anastrozole). Various clinicopathological parameters were recorded and analyzed
(chi-square test, Fisher’s exact test and logistic regression analysis).
Results: The mean observation period was 39.9 months. AIA manifested in 114 patients (34.8%), with peaks of
onset at 4 (33.7%) and 8 months (11.4%) after starting AI administration. Some cases manifested even after 13
months. AIA tended to occur in younger patients (incidences of 46.3%, 37.4% and 28.0% for ages of < 55, 55-65
and > 65 years, respectively (p = 0.063)) and decreased significantly with the age at menarche (53.3%, 35.3% and
15.4% for < 12, 12-15 and > 15 years, respectively (p = 0.036)). The incidences were 45.1%, 46.3 and 25.1% for the
time since the last menstrual period (LMP) < 5 years, 5-10 years and > 10 years, being significantly lower at > 10
years (p < 0.001). In logistic regression analysis, the AIA incidence was significantly lower in the time since LMP >
10-year group versus the < 5-year group (odds ratio 0.44, p = 0.002), but the age at menarche showed no
association. AIA manifested significantly earlier (≤ 6 months) as the time since LMP became shorter (< 5 years).
Conclusion: AIA tends to manifest early after starting AI, but some cases show delayed onset. The incidence was
significantly lower in patients with a duration of > 10 years since LMP. When the time since LMP was short, the
onset of AIA was significantly earlier after starting AI administration.
Background
Aromatase inhibitors (AI) have shown efficacy that is
superior to that of tamoxifen (TAM) in large-scale ran-
domized clinical studies, and they are now extensively
used as adjuvant therapy for patients with endocrine-
responsive, postmenopausal breast cancer [1,2]. How-
ever, aromatase inhibitor-related arthralgia (AIA) is a
problematic drug-related adverse reaction of AIs. The
incidence of AIA has been reported to be 20%-50% in
AI-administered patients [3-5] and, although the num-
ber of cases is small, it is sometimes necessary to
discontinue AI administration [6-11]. AIA manifests
most commonly during the first 3-6 months of AI
administration, and it was reported that its occurrence
is significantly higher when the time since the last
menstrual period (LMP) is short [12]. We have
reported similar results [13]. It is thought that a
decrease in serum E2 is involved in the onset of AIA
[14-20]. We also reported that a decrease in E2 is
indirectly involved in AIA manifestation [13], but the
details of the clinical predictors have never been eluci-
dated. Here, with the objective of identifying those
clinical predictors, we report the findings of our sur-
veillance of AIA in a prospective trial of patients being
administered an AI. * Correspondence: breast@mb.tcn.ne.jp
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This study enrolled a total of 390 postmenopausal breast
cancer patients who were administered an AI between Jan-
uary 2005 and October 2010 at Tokushima Breast Clinic.
The toxicity profiles of steroidal and non-steroidal aroma-
tase inhibitors are known to differ [11], and for that reason
we orally administered a non-steroidal AI, anastrozole, at
1 mg/day. The following patient data were recorded at the
time of enrollment of each patient: age, age at menarche,
number of child deliveries, BMI (the BMI cut-off values
were as reported previously [12]), the presence/absence of
arthralgia prior to AI administration, the time since LMP,
the presence/absence of therapy for breast cancer prior to
AI administration (excluding hormone replacement treat-
ment), Stage, the presence/absence of axillary node metas-
tasis, and estrogen receptor status. Surveillance for AIA
was performed prior to AI administration and, in princi-
ple, at 4-month intervals following the start of AI adminis-
tration. AIA was defined as new manifestation of joint
symptoms (pain or stiffness) following the AI administra-
tion or exacerbation of existing joint symptoms following
the AI administration. The assessment of AIA was per-
formed as patient-reported outcomes in accordance with
the Common Terminology Criteria for Adverse Events
(CTCAG) Version 4.0 [21]. In the case of patients with
joint symptoms prior to the start of AI administration, the
grade of the symptoms at the time of exacerbation was
assessed, and the pretreatment symptoms were not taken
into consideration. In the end, a total of 328 patients were
confirmed to have continuously ingested the AI drug for
at least 8 months after the start of administration and had
undergone sufficient clinical surveillance for inclusion in
this study. The presence/absence of AIA and the time of
onset of AIA were compared with the clinicopathological
findings. Statistical analysis was performed using the chi-
square test and Fisher’s exact test and univariate analysis
and multivariate analysis were performed using logistic
regression analysis. Variables that were not significant at
the 0.20 level in the bivariate analyses were not included.
A p value of < 0.05 was defined as representing a statisti-
cally significant difference in the chi-square test and Fish-
er’s exact test, and < 0.01 indicated significance in
multivariate analysis [12,14]. The design of this study was
approved by the Ethics Committees of The Institute of
Medical Science, The University of Tokyo (trial registra-
tion number: 19-11-1211), and The University of Tokush-
ima. Prior informed consent was obtained in writing from
each of the enrolled patients.
Results
Incidence and Time of Onset of AIA
The mean observation time for the 328 patients was
39.9 months (39.9 ± 19.8) (range 8.9-119.9), and AIA
manifested in 114 (34.8%) patients. Next, the time of
onset of the AIA following the start of AI administration
was investigated. The time of onset showed peaks at 4
months (33.7%) and 8 months (11.4%) after starting AI
administration, and there was onset in a small number
of patients even after more than 13 months (Figure 1).
Comparison of Presence/Absence of AIA and the Patient
Background Factors
The patient background factors were compared between
214 patients who manifested AIA and 114 patients who
did not. The incidence of AIA was 46.3% in patients aged
< 55 years, 37.4% in patients aged 55-65 years and 28.0%
in patients older than 65. There was a tendency for AIA
to manifest more frequently in younger patients (p =
0.063). When stratified on the basis of the age at
menarche, i.e., < 12 years, 12-15 years and > 15 years, the
incidences of AIA were 53.3%, 35.3% and 15.4%, respec-
tively, and AIA manifested significantly more frequently
as the age at menarche became lower (p = 0.036). The
incidence of AIA was 31.8% in patients with a BMI of <
25 and 40.7% in patients with a BMI of 25-30; there was
no correlation between the BMI and manifestation of
AIA. The time since LMP was stratified into < 5 years, 5-
10 years and > 10 years, and the incidences of AIA were
45.1%, 46.3% and 25.1%, respectively; the incidence was
significantly lower in the patients with time since LMP >
10 years (p < 0.001). With regard to the presence/absence
of treatment prior to the start of the AI administration,
stratification showed AIA incidences of 39.8% and 31.3%
in the presence and absence of prior therapy, respec-
tively. Although the AIA incidence was higher in the
patients who had undergone prior therapy, the difference
was not statistically significant. In addition, there were no
differences in the incidence of AIA as a function of the
number of child deliveries, stage, presence/absence of
lymph node metastasis, presence/absence of previous
hormonal therapy or whether or not a taxane was
included in the chemotherapy regimen (Table 1). Next,
logistic regression analysis was performed in relation to
the age at menarche and the time LMP, which had
shown significant differences in the incidence of AIA.
The results showed that, when the time since LMP < 5
years was used as the reference, the incidence of AIA in
the case of time since LMP > 10 years was significantly
lower, with an odds ratio of 0.44 (p = 0.002). On the
other hand, no statistically significant difference was
found in regard to the age at menarche (Table 2).
Comparison of the Time of Onset of AIA and the Patient
Background Factors
The time of onset of AIA and the patient background
factors were investigated for associations in the patients
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Page 2 of 6who manifested AIA. Only the time since LMP showed
a clear correlation with the onset of AIA. The time of
onset of AIA was divided into 2 groups (≤ 6m o n t h s
and > 6 months) or 3 groups (≤ 6 months, 7-12 months
and > 12 months). AIA was more likely to manifest
early after the start of AI administration (≤ 6m o n t h s )
as the time since LMP became shorter (< 5 years)
(Table 3).
Discussion
The incidence of AIA in this surveillance was 34.8%.
With regard to the time of onset of AIA, it had been
thought that most cases of AIA manifest within the first
6 months of administrationo fa nA I[ 1 2 ] .H o w e v e r ,i n
this investigation we found that the time of onset
showed two peaks, at 4 months and 8 months after
starting AI administration, and it was elucidated that
some cases manifested even after 13 months of treat-
ment. Such delayed onset was also reported in the
ATAC trial [3], and we thus confirmed the delayed
onset of AIA.
As factors involved in the onset of AIA, it has been
said that most cases develop in patients in whom the
time since the LMP is within 5 years and in the 50-59
year-old age bracket [12,22,23]. Our univariate analysis
found that AIA tended to increase in incidence in the
younger patients, while its incidence was significantly
lower in the patient group with a long time since LMP
and significantly higher as the age at menarche
decreased. In addition, multivariate analysis indicated
that the time since LMP was the only factor that corre-
lated significantly with the onset of AIA. Prior treat-
ment, obesity, etc., have been suggested to be other
factors that readily cause AIA, but there is no consensus
in his regard [22,23]. Our results found that onset of
AIA was more frequent in patients who had been trea-
ted previously and had a high BMI, but the differences
were not statistically significant.
Our analysis of patient background factors that might
be related to the time of onset of AIA indicated that
this adverse event was significantly more common when
the time since LMP was short. There was a peak of
onset of AIA at 4 months after starting administration
of the AI, but that is when we started our surveillance.
Thus, we were unable to determine more accurately the
onset of AI at an earlier time. There have been reports
that the most common time of onset was within 3
months after starting AI administration [12], and it can
be thought that it is a fact that there is a first peak of
manifestation soon after starting administration. It can
b et h o u g h tt h a tp a t i e n t sw i t has h o r tt i m es i n c eL M P
are more susceptible to the effects of a decrease in E2
due to an AI drug. It has been hypothesized that estro-
gen can modulate spinal and central processing of noci-
ception through opioid-containing neurons in the spinal
cord and brain that express estrogen receptors, and
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Figure 1 The time of onset of AIA showed peaks at 4 (33.7%) and 8 months (11.4%) after starting AI administration, and there was
onset in a small number of patients even after more than 13 months.
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Page 3 of 6Table 1 Comparison of Presence/Absence of AIA and the Patient Background Factors
Background w/o AIA(%) with AIA(%) P-value
n = 214 n = 114
Age (yrs) < 55 22(53.7) 19(46.3) NS*
55-65 97(62.6) 58(37.4)
65 < 95(72.0) 37(28.0)
Age at menarche (yrs) < 12 7(46.7) 8(53.3) P=0.036*
15-Dec 183(64.7) 100(35.3)
15 < 22(84.6) 4(15.4)
No. of childbirths 0 27(71.1) 11(28.9) NS*
2-Jan 132(63.5) 76(36.5)
2 < 53(66.3) 27(33.8)
Body mass index (kg/m2) < 25 150(68.2) 70(31.8) NS*
25-30 64(59.3) 44(40.7)
Past history of Arthritis Yes 48(71.6) 19(28.4) NS*
No 166(63.6) 95(36.4)
Time since LMP (yrs) < 5 39(54.9) 32(45.1) p < 0.001*
10-May 44(53.7) 38(46.3)
10 < 131(74.9) 44(25.1)
Pre-treatment (HT and/or CT) No 134(68.7) 61(31.3) NS*
Yes 80(60.2) 53(39.8)
Pre-treatment (HT) No 166(64.8) 90(35.2) NS**
Yes 48(66.7) 24(33.3)
With pre-treatment: (Chemo with taxane) No 17(51.5) 16(48.5) NS*
Yes 27(56.3) 21(43.8)
Stage 0 17(60.7) 11(39.3) NS**
I 112(62.9) 66(37.1)
II 80(70.8) 33(29.2)
III 5(62.5) 3(37.5)
IV 0 1
Metastasis to LNs Yes 68(63.6) 39(36.4) NS*
No 118(65.9) 61(34.1)
Nd 28 14
ER + 204(64.4) 113(35.6) NS**
- 10(90.9) 1(9.1)
AIA: aromatase inhibitor related arthralgia; LMP: last menstrual period;
HT: hormone therapy; CT: chemotherapy; Nd: not detected; ER: estrogen receptor;
w/o: without;
*:Chi-square test; **:Fisher’s exact test.
Table 2 Comparison of Presence/Absence of AIA and the Patient Background Factors
Background Univariate Multivariate P-value
Odds ratio(95%CI) Odds ratio(95%CI)
Time since LMP(yrs) p = 0.002*
< 5 Reference Reference
10-May 1.08(0.57-2.04) 1.10(0.58-2.09)
10 < 0.39(0.22-0.71) 0.44(0.24-0.80)
Age at menarche(yrs) p = 0.24*
< 12 Reference Reference
15-Dec 0.48(0.17-1.36) 0.60(0.21-1.76)
15 < 0.16(0.04-0.69) 0.29(0.06-1.33)
AIA: aromatase inhibitor related arthralgia; LMP: last menstrual period;
*: logistic regression analysis.
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Page 4 of 6hypoestrogenemia may increase pain sensitivity by
decreasing the pain threshold [5]. In addition, aromatase
is present in the osteoblasts, synovial cells and chondro-
cytes of articular cartilage, and there are reports that
surmise that local decreases in E2 in the bone and joints
are involved in AIA [4]. However, we think that these
two hypotheses might be involved in AIA when the
time since LMP is short.
On the other hand, carpal tunnel syndrome, wrist
effusion, tendon sheath enhancement and thickening,
and tendosynovial changes were reported in AIA
patients in a study that investigated the joint findings by
sonography performed at a mean of 12 months follow-
ing administration of an AI [24] and a study that per-
formed objective examination by magnetic resonance
imaging at 6 months following AI administration [25].
Those studies indicated the possibility that organic
changes occur in the joints, but it is difficult to believe
that they could manifest within a short period of time,
and that a certain length of time would be necessary for
them to occur.
I no u rp r e s e n ts t u d y ,w ef o u n dt h a tA I Ad i dn o t
manifest only in the early period after starting AI
administration, that it also occurred after a certain
amount of time had passed and that there was even
delayed onset of AIA. The time since LMP was long in
many of the patients with delayed onset of AIA, and
we surmise that the clinical predictors involved in
delayed AIA are different from those in patients with
early onset of AIA. It can be thought that, in the
future, it will be necessary to clarify the clinical predic-
tors of AIA by carrying out a prospective study that
employs E2 monitoring, image assessment using MRI
of the joints, etc., and accurate assessment of joint
movement [26] during the early period following the
start of AI administration.
Conclusion
AIA is most likely to manifest in the early period after
AI administration, but there are also cases of delayed
manifestation. It was surmised that the length of the
time since LMP is important for elucidating the
mechanism of the onset of AIA.
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